BeStock  
Stocks › Biotechnology › KYMR

Kymera Therapeutics KYMR

US equityMarket cap rank #1426Biotechnology
$115.31 −$4.08 (-3.42%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $124.06 +7.59%
Open$117.89
Prev close$119.39
Day range$114.40 – $119.60
Volume1.28M
Market cap$9.84B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00-100.0% YoY
Operating profit-$147.23M-66.1% YoY
Net profit-$132.00M-60.6% YoY
Diluted EPS-$1.32-40.4% YoY
Free cash flow-$78.23M-186.6% YoY
Operating cash flow-$77.91M

Revenue, last 8 quarters

$7.4MDec '24$22.1MMar '25$11.5MJun '25$2.8MSep '25$2.9MDec '25$34.4MMar '26$65.0MJun '26$0.0Sep '26

Net profit, last 8 quarters

$-70.8MDec '24$-65.6MMar '25$-76.6MJun '25$-82.2MSep '25$-87.0MDec '25$-69.2MMar '26$-61.2MJun '26$-132.0MSep '26

Diluted EPS by quarter

-0.88Dec '24-0.82Mar '25-0.95Jun '25-0.94Sep '25-0.97Dec '25-0.71Mar '26-0.62Jun '26-1.32Sep '26

Free cash flow by quarter

$-62.7MDec '24$-79.6MMar '25$-60.6MJun '25$-27.3MSep '25$-66.9MDec '25$-89.3MMar '26$-54.5MJun '26$-78.2MSep '26

Annual revenue

$34.0MFY20$72.8MFY21$46.8MFY22$78.6MFY23$47.1MFY24$39.2MFY25

Profitability & balance sheet

Operating margin-396.0%
Net margin-341.8%
Return on equity-27.3%
Return on assets-24.4%
Return on invested capital-29.8%
Current ratio11.13
Liabilities / assets8.6%
Cash & investments$971.21M
Total debt$63.02M
Net cash (debt)$908.20M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $0.00 $65.00M $34.37M $39.21M $2.87M
Total Operating Revenue $0.00 $65.00M $34.37M $39.21M $2.87M
Operating Expense $147.23M $140.61M $118.52M $384.76M $100.77M
Selling and Admin Expenses $18.72M $21.13M $20.36M $68.19M $16.94M
-General & Admin Expense $18.72M $21.13M $20.36M $68.19M $16.94M
Research & Development $128.51M $119.48M $98.16M $316.57M $83.83M
Operating Profit -$147.23M -$75.61M -$84.15M -$345.54M -$97.90M
Net Non-Operating Interest Income (Expense) $15.23M $14.40M $14.92M $38.05M $10.92M
Non-Operating Interest Income $15.30M $14.48M $14.98M $38.42M $11.01M
Non-Operating Interest Expense $62,000.00 $81,000.00 $61,000.00 $370,000.00 $90,000.00
Special Income (Charges) $0.00 – – -$3.86M $0.00
-Less:Impairment of Capital Assets $0.00 – – $3.86M $0.00
Pretax Profit -$132.00M -$61.21M -$69.23M -$311.35M -$86.98M
Net Profit -$132.00M -$61.21M -$69.23M -$311.35M -$86.98M
Profit from Continuing Operations -$132.00M -$61.21M -$69.23M -$311.35M -$86.98M
Net Income to Parent Company -$132.00M -$61.21M -$69.23M -$311.35M -$86.98M
Net Income to Common Stockholders -$132.00M -$61.21M -$69.23M -$311.35M -$86.98M
Basic EPS -$1.32 -$0.62 -$0.71 -$3.69 -$0.97
Diluted EPS -$1.32 -$0.62 -$0.71 -$3.69 -$0.97
Other Income (Expense) – – – -$3.86M $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.77B $1.65B $1.67B $1.74B $1.74B
Total Current Assets $998.59M $737.27M $677.43M $871.21M $871.21M
Cash and Cash Equivalents & Short-Term Investments $971.21M $690.99M $650.93M $848.28M $848.28M
-Cash and Cash Equivalents $373.37M $124.48M $144.09M $357.01M $357.01M
-Short Term Investments $597.84M $566.51M $506.84M $491.27M $491.27M
Other Current Assets $27.38M $26.28M $26.50M $22.94M $22.94M
Total Non-Current Assets $768.68M $908.18M $991.58M $871.60M $871.60M
Net PPE $78.69M $81.07M $83.35M $85.53M $85.53M
-Gross PPE $106.80M $107.16M $107.41M $107.65M $107.65M
-Accumulated Depreciation -$28.11M -$26.09M -$24.06M -$22.13M -$22.13M
Investments and Advances $674.67M $813.90M $894.72M $771.16M $771.16M
-Available for Sale Securities $674.67M $813.90M $894.72M $771.16M $771.16M
Other Non-Current Assets $15.32M $13.21M $13.51M $14.91M $14.91M
Total Liabilities $152.74M $136.19M $129.38M $163.15M $163.15M
Total Current Liabilities $89.72M $71.33M $62.64M $83.21M $83.21M
Payables $11.92M $8.92M $12.84M $4.02M $4.02M
-Accounts Payable $11.92M $8.92M $12.84M $4.02M $4.02M
Current Accrued Expenses $63.32M $48.48M $35.10M $42.27M $42.27M
Short-Term Debt and Capital Lease Obligation $13.58M $13.70M $13.73M $13.76M $13.76M
-Current Capital Lease Obligation $13.58M $13.70M $13.73M $13.76M $13.76M
Current Deferred Liabilities $0.00 $0.00 $0.00 $22.93M $22.93M
Other Current Liabilities $905,000.00 $236,000.00 $976,000.00 $242,000.00 $242,000.00
Total Non-Current Liabilities $63.02M $64.86M $66.74M $79.94M $79.94M
Long Term Debt and Capital Lease Obligation $63.02M $64.86M $66.74M $68.50M $68.50M
-Long Term Capital Lease Obligation $63.02M $64.86M $66.74M $68.50M $68.50M
Non-Current Deferred Liabilities $0.00 $0.00 $0.00 $11.44M $11.44M
Total Equity $1.61B $1.51B $1.54B $1.58B $1.58B
Stockholders' Equity $1.61B $1.51B $1.54B $1.58B $1.58B
Capital Stock $9,000.00 $8,000.00 $8,000.00 $8,000.00 $8,000.00
-Common Stock $9,000.00 $8,000.00 $8,000.00 $8,000.00 $8,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $2.96B $2.71B $2.68B $2.64B $2.64B
Retained Earnings -$1.33B -$1.20B -$1.14B -$1.07B -$1.07B
Gains/Losses Not Affecting Retained Earnings -$14.74M -$7.16M -$4.19M $1.80M $1.80M
Receivables – $20.00M – – –
-Accounts Receivable – $20.00M – – –

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$77.91M -$54.07M -$88.84M -$232.89M -$66.75M
Net cash flow from continuing operations -$77.91M -$54.07M -$88.84M -$232.89M -$66.75M
Net Income from Continuing Operations -$132.00M -$61.21M -$69.23M -$311.35M -$86.98M
Depreciation & Depletion & Amortization $2.02M $2.03M $2.02M $8.31M $2.03M
Change in Working Capital $34.83M -$11.50M -$34.91M $15.27M $5.79M
-Change in Receivables $20.00M -$20.00M $0.00 $947,000.00 $0.00
-Change in Prepaid Assets -$1.10M $223,000.00 -$3.57M -$2.36M -$322,000.00
-Change in Payables and Accrued Expense $17.86M $9.55M $1.62M $5.41M $12.17M
-Change in Other Current Assets -$1.07M $2.37M $615,000.00 $2.67M $5.47M
-Change in Other Current Liabilities -$1.52M -$1.48M -$1.36M -$5.04M -$1.33M
-Change In Other Working Capital $654,000.00 -$2.16M -$32.21M $13.64M -$10.20M
Net cash flow from investing $101.63M $20.05M -$142.84M -$521.06M -$394.40M
Net Cash Flow from Continuing Investing Activities $101.63M $20.05M -$142.84M -$521.06M -$394.40M
Net PPE Purchase and Sale -$315,000.00 -$473,000.00 -$434,000.00 -$1.45M -$106,000.00
Net Investment Purchase and Sale $101.95M $20.52M -$142.41M -$519.61M -$394.29M
Financing Cash Flow $225.57M $14.42M $18.77M $990.71M $705.22M
Net Cash Flow from Continuing Financing Activities $225.57M $14.42M $18.77M $990.71M $705.22M
Net Issuance Payments Of Debt -$444,000.00 -$436,000.00 -$425,000.00 -$1.49M -$416,000.00
Net Common Stock Issuance $215.39M – – $928.90M $656.23M
Proceeds from Stock Option Exercised $10.62M $14.86M $19.19M $63.31M $49.41M
Ending Cash Balance $379.58M $130.30M $149.90M $362.81M $362.81M
Net Change in Cash $249.28M -$19.60M -$212.91M $236.76M $244.07M
Beginning Cash Balance $130.30M $149.90M $362.81M $126.05M $118.74M
Free Cash Flow -$78.23M -$54.54M -$89.27M -$234.34M -$66.85M
Gain/Loss from Continuing Operations – – -$2.73M – –

Discussion

No comments yet — be the first to weigh in on KYMR.

Sign in to join the discussion.

Scroll to Top